Early changes in renal function do not appear to mediate cardiovascular risk with dapagliflozin plus semaglutide: a real-world observational hypothesis-generating cohort study
{{output}}
Background: Cardiovascular-kidney-metabolic (CKM) syndrome links heart failure (HF), myocardial infarction (MI), kidney disease, diabetes, and obesity. SGLT2 inhibitors and GLP-1 receptor agonists improve cardiovascular and renal... ...
